1. P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 study. (30th January 2023) Authors: D'Haens, G; Afzali, A; Filip, R; Rolim, A; Terry, N A; Salese, L; Sahoo, A; Frustaci, M E; Yang, Z; Andrews, J M; Danese, S; Hisamatsu, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗